Table 1.
Outcomes after LT for HCC
| Author | Patients, n | Criteria for LT | RR, % | RFS, % | OS rate, % | S (p < 0.05) NS (p > 0.05) |
|---|---|---|---|---|---|---|
| Al-Ameri et al. [38] | 589 | 2 years | 2 years | |||
| 365 | Within Milan* | 8.9 | 85.3 | S: * versus a | ||
| 224 | Beyond Milan# | 32.2 | 75.8 | S: * versus # | ||
| 537 | Within Hangzhoua | 15.8 | 82.7 | S: a versus b | ||
| 52 | Beyond Hangzhoub | 32.1 | 71.6 | |||
| 398 | Within AFP modelc | 11.8 | 86.5 | S: c versus d | ||
| 191 | Beyond AFPd | 30.3 | 71.3 | |||
|
| ||||||
| Shimamura et al. [19] | 965 | 5 years | 5 years | 5 years | ||
| 644 | Within Milana | 7.5 | 73.1 | 75.3 | ||
| 301 | Beyond Milan | 34.7 | 50.6 | 58.7 | ||
| 735 | Within 5-5-500 | 7.3 | 73.2 | 75.8 | ||
| 230 | Beyond 5-5-500 | 43.8 | 43.4 | 52.1 | ||
| 792 | Within Milan or 5-5-500e | 9.1 | 71.8 | 74.8 | ||
| 173 | Beyond Milan or 5-5-500f | 47.8 | 40.0 | 48.6 | ||
| Post hoc analysis | ||||||
| Within Milan/within 5-5-500 versus | S (RFS) | |||||
| beyond Milan/within 5-5-500 | ||||||
| Within Milan/within 5-5-500 versus | S (RFS, OS) | |||||
| within Milan/beyond 5-5-500 | ||||||
| Within Milan/within 5-5-500 versus | S (RFS, OS) | |||||
| beyond Milan/beyond 5-5-500 | ||||||
| Beyond Milan/within 5-5-500 versus | S (RFS, OS) | |||||
| beyond Milan/beyond 5-5-500 | ||||||
|
| ||||||
| Meischl et al. [17] | 216 | Median time 21.2 months 16.2 | 1/3/5/10 years | |||
| 82.4/73.8/70/50.9 | ||||||
| 132 | Within Milan*, c | 83.3/78.6/76.5/54.5 | ||||
| 84 | Beyond Milan*, d (within UT7 or UCSF) (*Milan based on explant histology, patients underwent downstaging if needed) | 79.5/64.6/58.3/42.5 | NS: c versus d | |||
| 5 years | ||||||
| CRP ≥1 mg/mLa | 83.5/74.1/70.4/51.4 | |||||
| (n = 39 within Milan*, | ||||||
| 31 beyond Milan) 16.4 | S: a versus b | |||||
| CRP <1 mg/mLb | 81.7/75/71.1/53.4 | |||||
| 27.4 | ||||||
|
| ||||||
| Kornberg et al. [15] | 5/7 years | 5/7 years | ||||
| 123 | 76.9/75.9 | 82.9/74.6 | ||||
| 69 | Within Milana | 86.8/86.8 | 82.5/80.3 | S: a vs c | ||
| 88 | Within UT7b | (RFS, OS) | ||||
| 54 | 81.6/81.6 | 78.3/74.9 | S: b vs d | |||
| 35 | (RFS, OS) | |||||
| Beyond Milanc | 61.8/61.8 | 64.3/58.9 | ||||
| Beyond UT7d | 61/61 | 61.4/61.4 | ||||
| Post hoc analysis | ||||||
| Within Milan/ALBI grade 1 | 96/96e | NS: e vs h, i | ||||
| Within Milan/ALBI grade 2 | 91.2/91.2f | |||||
| Within Milan/ALBI grade 3 | 44.4/44.4g | S: e, f vs d | ||||
| Beyond Milan/ALBI grade 1 | 75.5/75.5h | |||||
| Beyond Milan/ALBI grade 2 | 75/75i | |||||
| Beyond Milan/ALBI grade 3 | 17.6/17.6j | S: h, i vs j | ||||
| ORS (0–3) low | 94.2/94.2k | |||||
| ORS (4–6) high | 27/27l | S: k vs l | ||||
LT, liver transplantation; HCC, hepatocellular carcinoma; RR, recurrence rate; RFS, recurrence-free survival; OS, overall survival.